Studies on a Hib-tetanus toxoid conjugate vaccine: Effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine

Vaccine

Volumn 18, Issue 5-6, 1999, Pages 468-478

  Carlsson, Rose Marie ^a   Claesson, Bo A ^a   Käyhty, Helena ^b   Selstam, Urban ^c   Iwarson, Sten ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c Norra Alvsborgs Lanssjukhus S ^*  (Sweden)

Author keywords

Combination vaccine; Priming; Subcutaneous administration

Indexed keywords

BACTERIUM ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONJUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOGENICITY; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SWEDEN; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CLOSTRIDIUM TETANI; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; INFANT; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; TETANUS TOXOID; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 0032866083     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00238-8     Document Type: Article

References (35)

1. Granoff D.M., Rathore M.H., Holmes S.J., Granoff P.D., Luca A.H. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine. 11:1993;S46-S51.
2. Barington T., Gyhrs A., Kristensen K., Heilmann C. Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect. Immun. 62:1994;9-14.
3. Kurikka S. Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. Vaccine. 14:1996;1239-1242.
4. Claesson B.A., Trollfors B., Lagergård T., Taranger J., Bryla D., Otterman G., Cramton T., Yang Y., Reimer C.B., Robbins J.B., Schneerson R. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J. Pediatr. 112:1988;695-702.
5. Carlsson R-M., Claesson B.A., Iwarson S., Lagergård T., Käyhty H. Antibodies against Haemophilus influenzae type b and tetanus in infants after subcutaneous vaccination with PRP-T/diphtheria, or PRP-OMP/diphtheria-tetanus vaccines. Pediatr. Infect. Dis. J. 13:1994;27-33.
6. Claesson B.A., Schneerson R., Robbins J.B., Johansson J., Lagergård T., Taranger J., Bryla D., Levi L., Cramton T., Trollfors B. Protective levels of serum antibodies stimulated in infants by two injections of Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate. J. Pediatr. 114:1989;97-100.
7. Ferreccio C., Clemens J., Avendano A., Horwitz I., Flores C., Avila L., Cayazzo M., Fritzell B., Cadoz M., Levine M. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age. Pediatr. Infect. Dis. J. 10:1991;764-771.
8. Robbins J.B., Parke J.C. Jr, Schneerson R., Whisnant J.K. Quantitative measurement of 'natural' and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr. Res. 7:1973;103-110.
9. Kuo J.S.C., Monji N., Schwalbe R.S., McCoy D.W. A radioactive antigen-binding assay for the measurement of antibody to Haemophilus influenzae type b capsular polysaccharide. J. Immunol. Methods. 43:1981;35-47.
10. Manclark C.R., Meade B.D., Burstyn D.B. Serological response to Bordetella pertussis. Rose N.R., Friedman H., Fahey J.L. Manual of clinical laboratory immunology. 3rd ed. 1986;388-394 American Society of Microbiology, Washington DC.
11. Bizzini B. Tetanus. Germanier R. Bacterial vaccines. 1984;37-68 Academic Press, Orlando FL.
12. Miyamura K., Nishio S., Ito A., Murata R., Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using Vero cells: I. Studies on factors affecting the toxin and antitoxin titration. J. Biol. Strand. 2:1974;189-201.
13. Böttiger M. Polio immunity to killed vaccine: an 18-y follow-up. Vaccine. 8:1990;443-445.
14. Reed G.F., Meade B.D., Steinhoff M.C. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics. 96:1995;600-603.
15. Eskola J., Ölander R.M., Hovi T., Litmanen L., Peltola S., Käyhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet. 348:1996;1688-1692.
16. Fritzell B., Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide tetanus protein conjugate vaccine. J. Pediatr. 121:1992;355-362.
17. Carlsson R-M., Claesson B.A., Selstam U., Fagerlund E., Granström M., Blondeau C., Hoffenbach A. Safety and immunogenicity of a combined DTaP-IPV-Hib vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr. Infect. Dis. J. 17:1998;1026-1033.
18. Levine O.S., Granoff D.M., Lagos R., Fritzell B., Levine M.M. Factors associated with superior antibody responses to a single dose of Haemophilus influenzae type b - tetanus toxoid conjugate vaccine administered to Chilean infants at two months of age. Vaccine. 15:1997;325-328.
19. Castillo de Febres O., Decker M.D., Estopinan M., Bordones G., Edwards K.M. Enhanced antibody response in Venezuelan infants immunized with Haemophlus influenzae type b - tetanus toxoid conjugate vaccine. Pediatr. Infect. Dis. J. 13:1994;635-639.
20. Claesson B.A., Schneerson R., Lagergård T., Trollfors B., Taranger J., Johansson J., Bryla D., Robbins J.B. Persistence of serum antibodies elicited by Haemophilus influenzae type b - tetanus toxoid conjugate vaccine in infants vaccinated at three, five and 12 months of age. Pediatr. Infect. Dis. J. 10:1991;560-564.
21. Garpenholt Ö, Silfverdal S.A., Hugosson S., Fredlund H., Bodin L., Romanus V., Olcén P. The impact of Haemophilus influenzae type b vaccination in Sweden. Scand. J. Infect. Dis. 28:1996;165-169.
22. Käyhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals. 22:1994;397-402.
23. Granoff D.M., Lucas A.H. Laboratory correlates of protections against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunologic memory. Ann. NY Acad. of Science. 754:1995;278-288.
24. Rothstein E.P., Kamiya H., Nii R., Matsuda T., Berstein H.H., Long S.S., Hosbach P.H., Meschievitz C.K. Comparison of diphtheria-tetanus-two component acellular pertussis vaccines in United States and Japanese infants at two, four and six months of age. Pediatrics. 97:1996;236-242.
25. Lagergård T., Trollfors B., Claesson B.A., Karlberg J., Taranger J. Determination of neutralizing antibodies and specific immunoglobulin isotype levels in infants after vaccination against diphtheria. Eur. J. Clin. Microbiol. Infect. Dis. 11:1992;341-345.
26. Björkholm B., Granström M., Taranger J., Wahl M., Hagberg L. Influence of high titers of maternal antibody on the serologic response of infants to diphtheria vaccination at three, five and 12 months of age. Pediatr. Infect. Dis. J. 14:1996;846-850.
27. Galazka A.M., Robertson S.E. Immunization against diphtheria with special emphasis on immunization of adults. Vaccine. 14:1996;845-857.
28. Mellander L., Böttiger M., Hanson L.Å., Taranger J., Carlsson B. Avidity and titers of the antibody response to two inactivated poliovirus vaccines with different antigen content. Acta Paediatr. 82:1993;552-556.
29. Vidor E., Meschievitz C., Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr. Infect. Dis. J. 16:1997;312-322.
30. Böttiger M., Larsson B. Swedish inactivated polio vaccine: laboratory standardization and clinical experience over a 30-y period. Biologicals. 20:1992;267-275.
31. Böttiger M. A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 y. Scand. J. Infect. Dis. 19:1987;595-601.
32. Leung A.K., Chiu A.S., Siu T.O. Subcutaneous vs intramuscular administration of Haemophilus influenzae type b vaccine. J. R. Soc. Health. 109:1989;71-73.
33. Ipp M.M., Gold R., Goldbach M., Maresky D.C., Saunders N., Greenberg S., Davy T. Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics. 83:1989;679-682.
34. Berg R. Vaccines - today and tomorrow. Läkartidningen. 86:1989;337-339.
35. Peltola H., Aavitsland P., Hansen K.G., Jónsdóttir K.E., Nøkleby H., Romanus V. A five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. J. Infect. Dis. 179:1999;223-229.